EGFR and glioblastoma: Animals harboring GBM22 EGFR WT tumors survived longer than GBM22 EGFR/EGFRvIII tumors when treated with TMZ monotherapy, suggesting the addition of saracatinib preferentially improves response in GBM cells with more TMZ resistance.